Discover if this is a suitable investor for your startup. If they are we'll make a warm introduction for free. Otherwise, we'll connect you with matching investors.
SR One Capital Management is a prominent biotechnology venture capital firm founded to partner with visionary founders and entrepreneurs in the quest to translate innovative science into effective medicines. Established with a commitment to advancing healthcare, the firm operates from its offices in Redwood City, California, and London, United Kingdom. SR One is recognized for its strategic focus on companies that exhibit strong underlying fundamentals and clearly defined development pathways. This approach enables the firm to support the development of novel therapeutic solutions aimed at addressing a wide range of diseases.
Since its inception, SR One has cultivated a reputation for its rigorous investment strategy and deep understanding of the biotechnology landscape. The firm has successfully raised multiple funds, allowing it to maintain a robust portfolio of investments across various stages of company development, from preclinical to clinical phases. With a keen eye for innovation, SR One seeks to identify and nurture companies that are poised to make significant contributions to the healthcare sector.
SR One Capital Management specializes in investing in biotechnology companies that target a diverse array of diseases, including cardiometabolic disorders, central nervous system (CNS) conditions, immunology, infectious diseases, oncology, rare diseases, renal issues, and neuropsychiatry. The firm employs a back-and-build investment strategy, which allows it to engage with companies at various stages of development, from early preclinical research to advanced clinical trials.
This strategic approach not only facilitates the growth of innovative therapies but also ensures that SR One can leverage its transatlantic presence to access high-quality scientific research and investment opportunities across North America and Europe. By focusing on companies with strong fundamentals and clear development pathways, SR One aims to support the advancement of groundbreaking treatments that can significantly improve patient outcomes.
SR One Capital Management boasts a diverse portfolio of notable investments in the biotechnology sector. Among its key portfolio companies is AirNexis Therapeutics, Inc., which is dedicated to developing innovative therapeutics for pulmonary diseases. Additionally, the firm has invested in companies focused on gene-based immuno-oncology treatments aimed at solid tumors, as well as clinical-stage companies that are developing therapies for viral diseases and autoimmune conditions.
Other significant investments include transformative gene-based medicines targeting serious human diseases, a clinical-stage biopharmaceutical company focused on improving treatments for gout, and advanced inhaled anti-infectives designed to combat life-threatening lung infections. Furthermore, SR One supports clinical-stage companies that are addressing orphan renal diseases, showcasing its commitment to advancing healthcare solutions across a wide spectrum of medical challenges.
SR One Capital Management invests across multiple stages, including pre-seed, seed, seed-plus, Series A, Series B, and Series C. This broad investment range allows the firm to support companies at various points in their development journey.
The firm primarily focuses on biotechnology companies, particularly those involved in cardiometabolic, CNS, immunology, infectious disease, oncology, rare diseases, renal, and neuropsychiatry sectors. This diverse focus enables SR One to engage with a wide array of innovative healthcare solutions.
While specific pitch preferences are not detailed in the provided information, it is advisable for founders to prepare a comprehensive pitch that outlines their company's vision, development pathway, and the innovative aspects of their technology. Engaging with the firm through a warm introduction may also be beneficial.
SR One has a transatlantic presence, with offices in both Redwood City, California, and London, United Kingdom. This geographic reach allows the firm to access high-quality scientific opportunities across North America and Europe.
The specific check sizes that SR One typically invests are not mentioned in the source material. However, given their focus on various stages of development, it is likely that they adapt their investment amounts based on the needs and potential of the companies they support.
While detailed information on portfolio support is not provided, SR One's extensive network and expertise in the biotechnology sector suggest that they likely offer strategic guidance and resources to help their portfolio companies navigate the complexities of drug development and commercialization.
All trademarks, logos and brand names are the property of their respective owners. All company, product and service names used in this website are for identification purposes only. Use of these names, trademarks, and brands does not imply endorsement.